Pleasanton Biotech Firm Pays $528,335.74 to Settle Claims

A Pleasanton biological research company agreed to pay the sum to resolve allegations tied to federal NIH grant eligibility.

Updated on Nov. 13, 2026 in Business

Pleasanton Biotech Firm Pays $528,335.74 to Settle Claims

A Pleasanton biological research company agreed to pay $528,335.74 to resolve False Claims Act allegations, according to the U.S. Attorney's Office for the Northern District of California. The allegations are unproven, and no determination of liability has been made.

Why it matters

The case concerns whether federal small-business research grants were drawn by a firm that allegedly was ineligible for them. It highlights how grant rules on outside employment of principal investigators are enforced after awards are made.

The settlement totals $528,335.74 and covers two STTR awards and one SBIR award from the National Institutes of Health. The allegations remain unadjudicated, and the settlement carries no finding of liability.

The players

U.S. Attorney's Office for the Northern District of California

The federal prosecutor's office that announced the settlement and coordinated the investigation with HHS-OIG.

HHS-OIG

The Office of Inspector General of the U.S. Department of Health and Human Services, which investigates fraud in federal health programs.

The details

The settlement resolves allegations that the company failed to disclose that its principal investigator held outside full-time employment, a condition that bars such firms from receiving STTR and SBIR grants. The company applied for STTR grants in 2017 and an SBIR grant in 2023, and drew down funds under those awards through 2019 and 2024.

Timeline

  1. 2017: The company applied for STTR grants from the National Institutes of Health.

  2. 2019: The company drew down funds under the STTR awards through this year.

  3. 2023: The company applied for an SBIR grant from the National Institutes of Health.

  4. 2024: The company drew down funds under the SBIR award through this year.

  5. November 13, 2026: The U.S. Attorney's Office announced the settlement.

Industry Context

The settlement applies the False Claims Act to NIH Small Business Technology Transfer and Innovation awards, which require small firms to meet eligibility conditions for federally funded research. Enforcement of these eligibility rules through False Claims Act settlements shows how federal research dollars are policed after they are awarded.

Small research firms receiving federal grants must meet eligibility conditions, and failures can lead to repayment and civil penalties. Residents of Pleasanton and other grant-funded communities may see stricter disclosure rules applied to federally funded research.

The takeaway

Grant eligibility rules apply to the entire life of an award, not only at the application stage. Organizations receiving federal research funds should confirm ongoing compliance with personnel disclosure requirements.

Further reading

For related coverage, explore Healthcare news from the Pleasanton area.

More information

Suspected misuse of federal health funds can be reported through the HHS-OIG fraud reporting portal.